cabergoline has been researched along with Cardiovascular Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Kowalcze, K; Krysiak, R; Okopień, B | 3 |
| Basiak, M; Krysiak, R; Machnik, G; Okopień, B; Szkróbka, W | 1 |
| Descamps, P; Jeanneteau, P; Mercier, MB; Parot-Schinkel, E; Sentilhes, L | 1 |
| Krysiak, R; Okopien, B | 1 |
| Lamos, EM; Levitt, DL; Munir, KM | 1 |
| Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Beauchamp, MC; Li, L; Maingrette, F; Mamputu, JC; Renier, G; Serri, O | 1 |
| Brändle, M; Schmid, C | 1 |
| Arcoraci, V; Morgante, L; Savica, R; Tari, M; Trifirò, G | 1 |
1 review(s) available for cabergoline and Cardiovascular Diseases
| Article | Year |
|---|---|
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Topics: Animals; Biomarkers; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Humans; Hypoglycemic Agents; Risk Factors; Treatment Outcome | 2016 |
2 trial(s) available for cabergoline and Cardiovascular Diseases
| Article | Year |
|---|---|
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors | 2015 |
The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Adult; Biomarkers; Blood Glucose; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; E-Selectin; Enzyme-Linked Immunosorbent Assay; Ergolines; Female; Humans; Hyperprolactinemia; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Linear Models; Lipids; Male; Middle Aged; Obesity; Risk Factors; Tumor Necrosis Factor-alpha | 2006 |
8 other study(ies) available for cabergoline and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiometabolic profile of young women with hypoprolactinemia.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Carotid Intima-Media Thickness; Female; Fibrinogen; Genetic Diseases, Inborn; Glucose; Humans; Lactation Disorders; Prolactin; Risk Factors; Uric Acid | 2022 |
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid | 2022 |
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Cholesterol; Creatinine; Female; Fibrinogen; Glycated Hemoglobin; Hashimoto Disease; Humans; Hyperprolactinemia; Insulin Resistance; Lipoproteins, HDL; Prolactin; Risk Factors; Thyroiditis, Autoimmune; Uric Acid | 2023 |
Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
Topics: C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Glucose; Humans; Hyperprolactinemia; Pilot Projects; Prolactin; Risk Factors; Triglycerides; Uric Acid; Vitamin D; Vitamin D Deficiency; Vitamins | 2023 |
[Inhibition of lactation: end to the bromocriptin, long life to the carbergolin?].
Topics: Bromocriptine; Cabergoline; Cardiovascular Diseases; Ergolines; Female; France; Hormone Antagonists; Humans; Lactation | 2014 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss | 2004 |
The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Topics: Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Insulin Resistance; Obesity; Risk Factors | 2006 |
Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
Topics: Aged; Antiparkinson Agents; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Male; Parkinson Disease; Pergolide; Treatment Outcome | 2008 |